Does Molecularly Guided Therapy Change the Surgical Goals of Glioma Resection?
Brain and Behavior · 2026-11 · 16 (11)
DOI: 10.1002/brb3.71913 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain and Behavior, online erschienen am 06.11.2026. Verfasst von Naeem Ul Haq und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Bacha Khan Medical College, Mardan, Pakistan. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Molecular Targeted Therapy, Neurosurgical Procedures. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
For more than 20 years, the goal of glioma surgery has been to remove as much tumor as possible without compromising patient safety. Many retrospective studies support that greater extent of resection is often associated with longer survival. However, three recent developments have challenged this traditional approach. First, the 2021 World Health Organization classification introduced a molecular approach to glioma diagnosis, which made tumor biology an additional consideration, alongside imaging, in setting surgical targets. Second, the IDH‐targeted therapies, particularly vorasidenib for IDH‐mutant low‐grade gliomas, have made residual disease a clinically meaningful variable rather than a surgical failure. Third, early phase locoregional chimeric antigen receptor (CAR) T‐cell trials have suggested that the resection cavity may be an important site for treatment delivery. These developments raise a question: should the goal of glioma surgery remain the same when targeted and locoregional therapies are available? In this review, we examine the evidence for extent of resection and discuss how newer therapies may affect surgical decision‐making.
Methods
A structured literature search of PubMed, Scopus, and Web of Science (inception to May 2026) was conducted, and evidence quality was graded narratively.
Findings
We argue that these therapies do not replace maximal safe resection but reshape its application in clinical practice. Surgical planning may increasingly need to consider tissue sampling and access for future therapies alongside tumor removal. We also highlight five key controversies and outline five priorities for future research.
Conclusion
Based on the available evidence, we propose an oncofunctional‐immunotherapeutic framework in which molecular subtype is considered before surgery, the resection cavity is seen as a potential therapeutic site, and preservation of neurological function remains essential for enabling further treatment. These elements are not yet integrated into a single clinical framework.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Bacha Khan Medical College, Mardan, Pakistan.
- Department of Medicine, Khyber Girls Medical College, Peshawar, Pakistan.
- Khyber Medical College, Peshawar, Pakistan.
- Kabul University, Kabul, Afghanistan.
Zitieren
APA
Haq, N. U., Irshad, S. U., Ullah, I., Irshad, S. R., Mir, S., Khan, M. S., Mumtaz, A., Jamal, M. A., & Mubariz, J. (2026). Does Molecularly Guided Therapy Change the Surgical Goals of Glioma Resection?. Brain and Behavior, 16(11). https://doi.org/10.1002/brb3.71913
Vancouver
Haq NU, Irshad SU, Ullah I, Irshad SR, Mir S, Khan MS, et al. Does Molecularly Guided Therapy Change the Surgical Goals of Glioma Resection?. Brain and Behavior. 2026;16(11). doi:10.1002/brb3.71913
BibTeX
@article{Haq2026,
author = {Haq, Naeem Ul and Irshad, Sardar Umer and Ullah, Irfan and Irshad, Sardar Remsha and Mir, Shah and Khan, Muhammad Shaheer and Mumtaz, Ali and Jamal, Malik Ahsan and Mubariz, Jahan},
title = {Does Molecularly Guided Therapy Change the Surgical Goals of Glioma Resection?},
journal = {Brain and Behavior},
year = {2026},
volume = {16},
number = {11},
doi = {10.1002/brb3.71913}
}
EUVIMED